An earlier report incorrectly identified the individual who collapsed in the Oval Office as Novo Nordisk executive Gordon Finlay. It has been clarified that Finlay was not present, and the true identity of the individual remains unknown. We regret the error.
During a press conference held in the Oval Office today, a pharmaceutical executive collapsed, causing a stir.
The incident occurred while the man stood behind the US president as the Trump administration announced a new agreement on weight-loss medications, leading to a sudden collapse of his knees.
Following the incident, officials from the administration and pharmaceutical companies rushed to assist the individual to prevent him from falling. White House Press Secretary Karoline Leavitt explained that a representative from one of the companies had fainted during the ‘Most Favored Nations Oval Office Announcement’.
Leavitt reassured that medical personnel on-site attended to the individual, confirming his well-being. She further stated that the press conference would resume shortly as planned.
A statement released indicated, “During the Most Favored Nations Oval Office Announcement, a representative from one of the companies fainted.
“The White House Medical Unit promptly intervened, and the individual is now in stable condition. The Press Conference will proceed shortly.”
Following the incident, reporters were escorted out of the Oval Office while cabinet members attended to the individual, elevating his legs. The cause of his collapse remains undisclosed.
The press conference featured executives from pharmaceutical giants Novo Nordisk and Eli Lilly, alongside the Trump administration, unveiling a groundbreaking deal that could impact the healthcare industry. Under the agreement, the manufacturers of Ozempic, Wegovy, and Zepbound will offer their treatments directly to the public through TrumpRx, a new government website set to launch next year.
In a significant development for patients, the companies anticipate that an oral version of the medications could be priced at $149 (£113) per month, pending approval from the Food and Drug Administration. Additionally, individuals covered by Medicare or Medicaid facing diabetes and other approved conditions will benefit from reduced prices of the injectable versions, priced at $245 (£186) per month.
Opt for Daily Mirror as a ‘Preferred Source’ on Google News for timely access to the news that matters to you.
<p class